Article
Endocrinology & Metabolism
Xu Wang, Xue Zhao, Danrong Chen, Mingzhi Zhang, Wei Gu
Summary: A comparison of treatment regimens for T1D in children using a combination of meta-analysis and prospective cohort study revealed that CSII may be associated with better glycemic control and growth development without increasing the risk of long-term complications or delaying puberty.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Christian T. Ruff, Michelle Baron, KyungAh Im, Michelle L. O'Donoghue, Fred T. Fiedorek, Marc S. Sabatine
Summary: This study investigated the cardiovascular safety of ITCA 650 in patients with type 2 diabetes and/or at risk for ASCVD, showing non-inferiority compared to placebo in terms of cardiovascular events. However, the ITCA 650 group had more frequent adverse events, primarily due to an increase in gastrointestinal events. Further large-scale and long-term cardiovascular outcomes trials are needed to define the exact cardiovascular effects of ITCA 650 in this population.
Article
Endocrinology & Metabolism
Mark Warren, Bruce Bode, Jang I. Cho, Rong Liu, Janet Tobian, Thomas Hardy, Farai Chigutsa, Moshe Phillip, Barry Horowitz, Debra Ignaut
Summary: The study found that in patients with type 1 diabetes using CSII, URLi was more effective in improving postprandial glucose control and reducing time spent in hypoglycemia compared to lispro.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Lisa A. Amato, Romana Kalolo, William Yu, David Simmons
Summary: This study reports on five patients with type 1 diabetes who underwent continuous subcutaneous insulin infusion therapy. After 2-4 months of treatment, the mean HbA1c level decreased from 9.7% to 7.9%. The frequency of hospital admissions for acute glycaemic events decreased in three patients but increased in two within 6 months. Some patients experienced a decrease in insulin dose and body mass index, and anecdotal evidence suggested increased satisfaction. Not all "frequent flyers" benefited from CSII.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Endocrinology & Metabolism
Jesus Moreno-Fernandez, Ana Chico, Maria Asuncion Martinez-Brocca, Pilar Isabel Beato-Vibora, Merce Vidal, Maria Piedra, Carmen Quiros, Jose Ramon Munoz-Rodriguez
Summary: This study analyzed the clinical effect of continuous subcutaneous insulin infusion (CSII) in the Spanish real-world scenario for patients with type 1 diabetes mellitus (T1D). The findings showed that CSII treatment was associated with a sustained improvement in glycemic control, especially among patients with higher CGM adherence.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Review
Chemistry, Medicinal
Hui Li, Aimin Yang, Shi Zhao, Elaine Yk Chow, Mohammad Javanbakht, Yinhui Li, Dandan Lin, Lijuan Xu, Deng Zang, Kai Wang, Li Ma
Summary: The clinical efficacy of continuous subcutaneous insulin infusion (CSII) therapy combined with six classes of oral glucose-lowering drugs (GLDs) in the treatment of type 2 diabetes was evaluated using a network meta-analysis. The results showed that CSII combined with metformin had the best clinical effect in controlling blood sugar and improving insulin resistance.
Article
Endocrinology & Metabolism
Alexis M. McKee, Noor Al-Hammadi, Leslie J. Hinyard
Summary: A study on young adults with type 1 diabetes found lower utilization of CSII in Black, Hispanic, male, and government-insured individuals, who also had higher HbA1c levels. Black, Hispanic, and government-insured subjects had higher odds of DKA.
ENDOCRINE PRACTICE
(2021)
Article
Medicine, General & Internal
Jennifer McVean, Gregory P. Forlenza, Roy W. Beck, Colleen Bauza, Ryan Bailey, Bruce Buckingham, Linda A. DiMeglio, Jennifer L. Sherr, Mark Clements, Anna Neyman, Carmella Evans-Molina, Emily K. Sims, Laurel H. Messer, Laya Ekhlaspour, Ryan McDonough, Michelle Van Name, Diana Rojas, Shannon Beasley, Stephanie DuBose, Craig Kollman, Antoinette Moran, CLVer Study Grp
Summary: The study aimed to determine the effectiveness of intensive diabetes management to achieve near normalization of glucose levels on preservation of pancreatic beta cell function in youth with newly diagnosed type 1 diabetes. The results showed that although the intensive management group achieved excellent glucose control, it did not affect the decline in pancreatic C-peptide secretion at 52 weeks.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Engineering, Biomedical
Shereen Kesserwan, Adam Mulka, Roshanak Sharafieh, Yi Qiao, Rong Wu, Donald L. Kreutzer, Ulrike Klueh
Summary: The presence of phenolic compounds in commercial insulin preparations may be toxic to cells and tissues, contributing to the failure of effective insulin infusion therapy.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
(2021)
Article
Endocrinology & Metabolism
Jennifer Leohr, Mary Anne Dellva, Elizabeth Labell, David E. Coutant, Jorge Arrubla, Leona Plum-Moerschel, Eric Zijlstra, Tsuyoshi Fukuda, Thomas Hardy
Summary: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection.
DIABETES OBESITY & METABOLISM
(2023)
Article
Public, Environmental & Occupational Health
Keyu Guo, Jiaqi Li, Liyin Zhang, Jianan Ye, Li Fan, Zhiyi Ding, Qin Zhou, Xia Li, Lin Yang, Zhiguang Zhou
Summary: This study compared the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy in Chinese patients with type 1 diabetes mellitus (T1DM). The results showed that CSII therapy was associated with lower HbA1c levels and better glycemic outcomes. However, it did not improve the risk of hypoglycemia.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Laura J. Reid, Fraser W. Gibb, Helen Colhoun, Sarah H. Wild, Mark W. J. Strachan, Karen Madill, Baljean Dhillon, Shareen Forbes
Summary: This study compared the progression of diabetic retinopathy in patients with type 1 diabetes who received CSII therapy versus MDI therapy. The results showed that CSII therapy was associated with reduced progression of diabetic retinopathy compared to continued MDI therapy, especially for patients with high baseline HbA(1c). The progression of retinopathy over 3 years was not affected by changes in HbA(1c).
Article
Multidisciplinary Sciences
Emma S. Scott, Andrzej S. Januszewski, Luke M. Carroll, Gregory R. Fulcher, Mugdha V. Joglekar, Anandwardhan A. Hardikar, Timothy W. Jones, Elizabeth A. Davis, Alicia J. Jenkins
Summary: Early use of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) may help reduce glycemic variability and have an impact on the expression of certain miRNAs related to diabetes vascular complications.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Tugba Barlas, Mehmet Muhittin Yalcin, Meric Coskun, Dilek Demirel, Alev Eroglu Altinova, Fusun Balos Toruner, Mehmet Ayhan Karakoc, Ilhan Yetkin, Mujde Akturk
Summary: The objective of this study was to determine lipohypertrophy (LH) in patients with type 1 diabetes mellitus on multiple daily insulin injections (MDII) or continuous subcutaneous insulin infusion (CSII) and to identify factors associated with LH development and severity. LH localizations were detected using palpation and ultrasonography (USG), with USG showing a significantly higher detection rate in the whole group. LH was more severe in the MDII group than in the CSII group, and its severity was positively correlated with HbA1C and insulin dose. MDII as an insulin administration method, incorrect rotation technique, and a history of ketosis were found to be the most related factors with LH severity.
ENDOCRINE PRACTICE
(2023)
Article
Endocrinology & Metabolism
Sebastian M. N. Heimburger, Bjorn Hoe, Chris N. Nielsen, Natasha C. Bergmann, Bolette Hartmann, Jens J. Holst, Tina Vilsboll, Thomas F. Dejgaard, Mikkel B. Christensen, Filip K. Knop
Summary: In men with type 1 diabetes, a 6-day subcutaneous GIP infusion did not have a convincing effect on overall time in range, but increased time in the tight glycemic range during the day by approximately 2 hours per day.